Berlin Cures announces changes to Board of Directors to further propel the
development of BC 007

Issuer: Berlin Cures Holding AG / Key word(s): Personnel
Berlin Cures announces changes to Board of Directors to further propel the
development of BC 007

26.06.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

  * Berlin Cures announces the appointment of Craig T. Basson, Gerrard
    Terlouw, and Oliver von Stein to its Board of Directors, succeeding Ulf
    Berg, Georg Nederegger, and Johannes Müller.

  * New board members will strengthen preparation for the Long COVID Phase
    II trial data read-out and shape the future development strategy, as
    well as business development and licensing.

  * Cardiovascular disease and Long COVID remain strategic priorities, with
    the in-house platform technology offering further opportunities.

Berlin, Germany, 26 June 2024 - Berlin Cures, a pioneer in the use of
aptamer-based therapeutics in autoimmune diseases, announced important
changes to its Board of Directors today. The aim is to further drive the
development of the company's lead drug candidate BC 007, currently in a
Phase II clinical trial for Long COVID. Berlin Cures welcomes three
distinguished new members who bring a wealth of knowledge and strategic
insight to its board of directors:

Craig T. Basson, MD, PhD, is a renowned physician-scientist with more than
25 years of experience in cardiovascular medicine. His research and
leadership roles in the pharmaceutical industry have provided him with
extensive experience in drug development with a particular focus on
cardiovascular disease. Gerrard Terlouw, PhD, MBA is an experienced
corporate and business development executive with more than 20 years of
leadership experience in the pharmaceutical industry. He has a proven track
record of successful licensing and acquisition deals across multiple
therapeutic areas. In addition, Berlin Cures' CEO Oliver von Stein, PhD,
will join the Board of Directors, bringing his extensive management
experience from various executive roles in the pharmaceutical industry and
from leading Berlin Cures as CEO.

Following these new appointments, Ulf Berg, Johannes Müller and Georg
Nederegger will step down from the Board of Directors with immediate effect
after many successful years. Johannes Müller will continue in his role as
Chief Science Officer as part of Berlin Cures' management team and will
continue to drive the company's research activities.

"We are delighted to welcome Craig Basson, Gerrard Terlouw and Oliver von
Stein to our Board of Directors. Their invaluable experience in clinical
development, immunology, cardiovascular disease and business development
will be instrumental as we continue to advance our BC 007 platform.
Together, we are poised to make a significant impact on the lives of
patients worldwide", states Rainer Böhm, Chairman of the Board of Berlin
Cures. "On behalf of the entire board and management team, I would like to
express my deep gratitude to Ulf Berg, Johannes Müller, and Georg Nederegger
for their vital support over the past years. Their expertise and guidance
have been instrumental in achieving Berlin Cures' latest milestones, such as
the current trials in Long COVID and heart failure. As we remain in close
contact, we will continue to benefit from their experience and advice."

Berlin Cures is at the forefront of developing innovative aptamer-based
drugs to neutralize pathogenic functional autoantibodies (fAABs) that
contribute to a variety of autoimmune diseases, including Long COVID, heart
failure, glaucoma, ME/CFS and many more. The company's lead drug candidate
BC 007 (Rovunaptabin) targets these harmful fAABs and hence has the
potential to address the root cause of various autoimmune diseases. The
company is currently conducting a Phase II trial with BC 007 in the
indication Long COVID, with initial results expected in Q4 2024, and has
already completed a Phase IIa study with BC 007 in heart failure.

In parallel, Berlin Cures is preparing for a subsequent Phase III study in
Long COVID which will be crucial for market approval. The company is
actively seeking funding partners to be able to initiate Phase III as soon
as possible following a successful outcome of Phase II.

Please find further information about the Board of Directors here.

About Berlin Cures:
The Berlin Cures team has dedicated over two decades to the research of
functional autoantibodies (fAABs) and has successfully identified a molecule
capable of effectively neutralizing these. Promising preclinical results
have been observed for BC 007. In a recently completed Phase IIa trial with
patients with chronic heart failure, BC 007 demonstrated long-term
autoantibody neutralization after a single dose resulting in significant
improvement in cardiac function. Its potential as an effective therapy for
Long COVID was realized when tests on sera from Long COVID patients proved
positive for fAABs, supported by clinical observations in four case studies.
By addressing the underlying cause of fAAB-associated diseases with this
unique biotechnology, Berlin Cures emerges as one of the pioneering entities
committed to addressing this critical issue at its core.

Berlin Cures is currently running a Phase II clinical trial with BC 007 in
the indication Long COVID, an acute and escalating global health problem, to
obtain meaningful and robust results on efficacy and tolerability. Initial
results are expected in Q4 2024.

Contact:
FGS Global
E-Mail: berlincures-eu@fgsglobal.com


---------------------------------------------------------------------------

Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------